APPEAR-C3G

Overview

The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to placebo and standard of care in patients with native C3G. The study aims to provide support for an iptacopan profile that includes stabilization of eGFR, clinically meaningful reductions in proteinuria and inhibition of the complement AP. 

Contact us

For more information contact Ryan.Oakes@childrenscolorado.org